Treatment relative effect with 95% CI; and degree of certainty (adaptated from GRADE). method
Treament | Trials | |||||
---|---|---|---|---|---|---|
Demonstrated or suggested benefit | Inconclusive results | Uncertain results | Safety results | |||
Immunostimulants drugs | inconclusive results for: death D28; deaths; hospitalization; mechanical ventilation; viral clearance ; viral clearance (time to event analysis only); emergent treatment-resistant variants; serious adverse events; adverse events | suggested 76 % decrease in clinical deterioration but the degree if certainty is unassessable demonstrated 44 % decrease in symptomatic Covid-19 but the degree if certainty is unassessable | - | |||
anti-inflammatory therapies | none | inconclusive results for: death D28; deaths; hospitalization or death; hospitalization; mechanical ventilation; recovery; related AE (TRAE); serious adverse events | - | - | ||
corticosteroids | none | inconclusive results for: death D28; deaths; hospitalization or death; clinical improvement (14-day); clinical improvement (28-day); clinical improvement (7-day); hospitalization; recovery; adverse events | - | - | ||
inhaled corticosteroids | inconclusive results for: hospitalization or death; clinical improvement (14-day); mechanical ventilation; ICU admission | demonstrated 84 % decrease in clinical deterioration but the degree if certainty is unassessable demonstrated 21 % increase in recovery but the degree if certainty is unassessable | - | |||
Apilimod | 0 | - | - | - | - | |
Immunosuppressants drugs | 0 | - | - | - | - | |
Kinase inhibitors | 0 | - | - | - | - | |
leflunomide | 0 | - | - | - | - | |
meplazumab | 0 | - | - | - | - | |
pirfenidone | 0 | - | - | - | - | |
Polyinosinic-Polycytidylic Acid | 0 | - | - | - | - | |
sargramostim | 0 | - | - | - | - | |
statins | 0 | - | - | - | - | |
thymosin | 0 | - | - | - | - |